Peptide Comparison
Ipamorelin vs GHRP-2
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
This combination is flagged
Two GHRPs in the same regimen: Moderate risk per peptide research literature. Ghrelin receptor (GHS-R1a) saturation + accelerated desensitization; may blunt long-term GH response.
Data-derived verdict
Ipamorelin and GHRP-2 share the ghrp / gh-secretagogue classes and carry roughly equivalent evidence (Anecdotal + Phase 2 / Japan-Approved Diagnostic). On the catalogued data layer Ipamorelin has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Ipamorelin's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Ipamorelin | GHRP-2 | |
|---|---|---|
| Class | Growth hormone-releasing peptide (GHRP); ghrelin receptor agonist | GHRP; ghrelin receptor agonist |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | Selective GHS-R1a (ghrelin receptor) agonist on pituitary; no cortisol or prolactin rise | GHS-R1a agonist; strong GH release |
| Route | SC injection | SC / Intranasal |
| Half-life | ~2 hrs | ~15-30 min |
| Dosage (research) | 200 mcg SC 2x daily (Seeds Vol 1 starting protocol, range up to 300 mcg 3x daily per r/Peptides wiki, often stacked with CJC-1295 no-DAC) | 100-300 mcg SC 1-3x daily |
| Evidence tier | Anecdotal + Phase 2 | Japan-Approved Diagnostic |
| Research depth | 64 indexed | 148 indexed |
| Availability | Compounding Restricted | Research |
| Reported risks | Mild fatigue; headache; injection site reactions; elevated IGF-1 theoretical | Cortisol/prolactin increase; hunger; water retention |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Ipamorelin or GHRP-2?
Ipamorelin and GHRP-2 share the ghrp / gh-secretagogue classes and carry roughly equivalent evidence (Anecdotal + Phase 2 / Japan-Approved Diagnostic). On the catalogued data layer Ipamorelin has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Ipamorelin's evidence base is currently denser.
What is the difference between Ipamorelin and GHRP-2?
Ipamorelin is classed as Growth hormone-releasing peptide (GHRP); ghrelin receptor agonist; GHRP-2 is classed as GHRP; ghrelin receptor agonist. Reported mechanism: Ipamorelin, Selective GHS-R1a (ghrelin receptor) agonist on pituitary; no cortisol or prolactin rise; GHRP-2, GHS-R1a agonist; strong GH release. Reported half-life: Ipamorelin, ~2 hrs; GHRP-2, ~15-30 min. Routes in published studies: Ipamorelin, SC injection; GHRP-2, SC / Intranasal.
Which has stronger evidence, Ipamorelin or GHRP-2?
Ipamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Ipamorelin is graded Anecdotal + Phase 2, with 9 cited sources on its reference page and 64 indexed studies. GHRP-2 is graded Japan-Approved Diagnostic, with 1 cited source on its reference page and 148 indexed studies.
Which is more accessible, Ipamorelin or GHRP-2?
Neither Ipamorelin nor GHRP-2 is an FDA-approved drug. Catalog status: Ipamorelin, Compounding Restricted; GHRP-2, Research. FDA lists Ipamorelin in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023). FDA lists GHRP-2 in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).
Are Ipamorelin and GHRP-2 ever combined?
Ipamorelin and GHRP-2 appear together in no stack catalogued on PeptideHelper.org. PeptideHelper.org's interaction engine flags the pair: Two GHRPs in the same regimen, moderate risk.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…